A phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) versus placebo in combination with background methotrexate in patients with active rheumatoid arthritis and an inadequate response to methotrexate alone

• Published in: Arthritis & rheumatology (Hoboken, N.J.) Vol. 64; no. 4; pp. 970 - 981
• Main Authors: Kremer, Joel M., Cohen, Stanley, Wilkinson, Bethanie E., Connell, Carol A., French, Jonathan L., Gomez-Reino, Juan, Gruben, David, Kanik, Keith S., Krishnaswami, Sriram, Pascual-Ramos, Virginia, Wallenstein, Gene, Zwillich, Samuel H.
• Format: Journal Article
• Language: English
• Published: Hoboken Wiley Subscription Services, Inc., A Wiley Company 01.04.2012; Wiley; Wiley Subscription Services, Inc
• Subjects: Adult; Aged; Antirheumatic Agents - administration & dosage; Antirheumatic Agents - therapeutic use; Arthritis, Rheumatoid - drug therapy; Biological and medical sciences; Bones, joints and connective tissue. Antiinflammatory agents; Diseases of the osteoarticular system; Dose-Response Relationship, Drug; Double-Blind Method; Drug therapy; Drug Therapy, Combination; Female; Humans; Inflammatory joint diseases; Male; Medical sciences; Methotrexate; Methotrexate - administration & dosage; Methotrexate - therapeutic use; Middle Aged; Pharmacology. Drug treatments; Piperidines; Pyrimidines - administration & dosage; Pyrimidines - therapeutic use; Pyrroles - administration & dosage; Pyrroles - therapeutic use; Rheumatoid arthritis; Treatment Outcome; Antineoplastic agent; Human; Immunopathology; Diseases of the osteoarticular system; Rheumatology; Oral administration; Autoimmune disease; Inflammatory joint disease; Chronic; Rheumatoid arthritis; Antirheumatic agent; Methotrexate; Dose; Comparative study

Objective To compare the efficacy, safety, and tolerability of 6 dosages of oral tofacitinib (CP‐690,550) with placebo for the treatment of active rheumatoid arthritis (RA) in patients receiving a stable background regimen of methotrexate (MTX) who have an inadequate response to MTX monotherapy. Met...